American Journal of Respiratory and Critical Care Medicine 2018;197:A7309 RATIONAL: Malignant pleural effusion (MPE) is a common disorder in patients suffering from advanced cancer. The short-lived survivals of this disease may be compromised by MPE. As these effusions can be resistant to the current treatment such as systemic chemotherapy, pleurodesis with sclerosant agents and recurrent drainage new therapeutic options are required. This study was aimed to evaluate the effectiveness of intrapleural chemotherapy with Cisplatin in order to manage MPE in lung, breast and mesothelioma cancers. METHODS: Twenty-one cancerous patients with MPE participated in this study. They all received Cisplatin through a catheter at a dose of 30mg/m2. The procedure was performed 3 times in two-weeks intervals. Patients were monitored for side effects and responses to the treatment every two weeks and also one month after the last procedure. RESULTS … CITE THIS ARTICLE: Abedini A, Kiani A, Taghavi K, Razavi F, Esmaeilzadeh M, Pourabdollah M, Khosravi A, Seifi S, Seyedi SR. Evaluation of Intrapleural Chemotherapy with Cisplatin in Patients with Malignant Pleural Effusion. InD61. IMAGING, INTERVENTIONS, AND INTERVENTIONAL PULMONOLOGY: THE THREE" I's" OF THORACIC ONCOLOGY 2018 May (pp. A7309-A7309). American Thoracic Society. https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A7309 https://scholar.google.co.in/scholar?hl=en&as_sdt=0%2C5&q=Evaluation+of+Intrapleural+Chemotherapy+with+Cisplatin+in+Patients+with+Malignant+Pleural+Effusion&btnG=
ResearchGate has not been able to resolve any citations for this publication.
ResearchGate has not been able to resolve any references for this publication.